The Philips Azurion interventional imaging system was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.
New technology now being considered by the FDA for approval can capture coronary inflammation on CCTA images and provide risk assessments. What could this mean for the future of cardiac care? We spoke to one researcher to learn more.
Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.
The algorithm has an edge over standard black box-style artificial intelligence applications because providers are able to see how it reaches conclusions.
The partnership will enable radiologists to more seamlessly access and post-process images acquired on Siemens Healthineers’ photon-counting CT scanners.
These findings present additional evidence that invasive imaging tests are not necessarily more effective when it comes to evaluating patients for chest pain.
